Clinical trials: Type II Diabetes Mellitus
Type 2 Diabetes Mellitus
A Study to Assess Insulin Delivery With PaQ® in Patients With Type 2 Diabetes Mellitus
The purpose of the study is to obtain an assessment (efficacy, safety, and patient reported outcomes) of basal bolus insulin delivery with PaQ in insulin-using patients with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT02419859
- Testing
- PaQ® Insulin Delivery Device, Insulin, Asp(B28)-
- Where
- Austria
- Volunteers
- 20 people
- Sponsor
- CeQur Corporation
Type 2 Diabetes
Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes
Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to evaluate the efficacy and safety in adult patients who have inadequate glycaemic control when treated…
- Trial name
- NCT00661362
- Testing
- Saxagliptin, Metformin
- Where
- 30 sites in China, India and 1 more
- Volunteers
- 570 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and renal impairment, with inadequate glycemic control on basal insulin alone or a…
- Trial name
- NCT06297603
- Testing
- Retatrutide
- Where
- 76 sites in United States, Argentina and 5 more
- Volunteers
- 320 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study
This study compares the effect on blood sugar levels of two medicines: insulin degludec and insulin glargine in people with type 2 diabetes.
- Trial name
- SWITCH PRO (NCT03687827)
- Testing
- Insulin degludec, Insulin glargine
- Where
- 67 sites in United States, Canada and 4 more
- Volunteers
- 498 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
A Study to Demonstrate Pharmacokinetic and Pharmacodynamic Biosimilarity Between HEC-Glargine and US-Lantus® in Healthy Male Volunteers
This is a phase 1 study to demonstrate pharmacokinetic and pharmacodynamic similarity between HEC-Glargine and US-Lantus® using the euglycemic clamp technique in healthy male adult volunteers.
- Trial name
- NCT05248841
- Testing
- HEC-Glargine, US-Lantus
- Where
- South Africa
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Lannett Company, Inc.
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy
The purpose of the study is to study the clinical effects of the investigational drug, SB-509 versus placebo in patients with diabetic neuropathy.
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Polyneuropathy
- Trial name
- NCT00476931
- Testing
- SB-509
- Where
- 20 sites in United States, Mexico
- Volunteers
- 91 people
- Sponsor
- Sangamo Therapeutics
Diabetes Mellitus, Type 2
Daily Use of JARDIANCE® Tablets in Japanese Elderly Patients With Type 2 Diabetes Mellitus
Study to investigate the safety and efficacy of daily use of JARDIANCE® Tablets in Japanese elderly patients with type 2 diabetes mellitus.
- Trial name
- NCT02367131
- Testing
- JARDIANCE®
- Where
- Japan
- Volunteers
- 419 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes
Study of Exenatide Once-Weekly Suspension in Chinese Patients With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the pharmacokinetics, tolerability, and safety of single and multiple doses of exenatide once-weekly suspension via subcutaneous (SC) injection using a pre-filled, single-dose autoinjector…
- Trial name
- NCT04001231
- Testing
- Exenatide Once-Weekly Suspension
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Multiple Dose Study of MK-2828 in Participants With Type 2 Diabetes (MK-2828-003)
The purpose of this study is to learn about the safety and if people tolerate a study medicine called MK-2828. The study will also measure what happens to MK-2828 in the body of a person with type 2 diabetes (T2D) over time…
- Trial name
- NCT07089784
- Testing
- MK-2828
- Where
- 11 sites in United States
- Volunteers
- 46 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/10/1000mg in Healthy Volunteers
This study is a randomized, open-label, single dose, crossover study to evaluate the pharmacokinetics and safety of CKD-383 in healthy volunteers.
- Trial name
- NCT07304700
- Testing
- CKD-383 0.5/10/1000mg, CKD-501, D744, D150
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Type2diabetes, Endothelial Dysfunction
A Trial to Evaluate the Effect of C21 on Endothelial Dysfunction in Subjects With Type 2 Diabetes
This trial is a single-centre, randomized, double-blind, placebo-controlled, 2-way cross-over phase 1b trial evaluating the pharmacodynamic effect of C21 on endothelial dysfunction and safety in subjects with type 2 diabetes…
- Trial name
- NCT05831644
- Testing
- C21
- Where
- Sweden
- Volunteers
- 11 people
- Sponsor
- Vicore Pharma AB
Type 2 Diabetes Mellitus
A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone
This is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study to determine the effect of ranolazine when added to metformin on glycemic control in adults with type 2 diabetes mellitus (T2DM) who are…
- Trial name
- NCT01555164
- Testing
- Ranolazine, Metformin, Diet
- Where
- 146 sites in United States, Canada and 9 more
- Volunteers
- 442 people
- Sponsor
- Gilead Sciences
Diabetes Mellitus, Type 2
Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors
Empagliflozin (Jardiance), a highly potent and selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2), was approved in Europe in May 2014 for the treatment of type 2 diabetes mellitus (T2DM) to improve glycaemic…
- Trial name
- NCT02864914
- Testing
- Empagliflozin, DPP-4 inhibitors
- Where
- United Kingdom
- Volunteers
- 333,580 people
- Sponsor
- Boehringer Ingelheim
Type II Diabetes Mellitus
Safety and Tolerability of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients Treated With Metformin and Sulfonylurea
The primary aim of this study is to evaluate the safety and tolerability of AZD1656 in T2DM patients treated with metformin and sulfonylurea.
- Trial name
- NCT00995787
- Testing
- AZD1656
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
An International Survey of the Occurrence of Diseases That Affects the Heart and Blood Vessels Among People With Type 2 Diabetes
The purpose of the study is to register the occurrence of cardiovascular disease among type 2 diabetes (T2DM) patients across five selected countries in Europe. Participants will be asked to give information about their health.
- Trial name
- EU-CAPTURE (NCT03786406)
- Testing
- No treatment given
- Where
- 41 sites in Czechia, France and 1 more
- Volunteers
- 2,275 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Effects of ISIS 113715 on Insulin Sensitivity, Glucose, and Lipid Metabolism and Energy Expenditure in Type 2 Diabetics
The aim of this study is to examine the effects of ISIS 113715 monotherapy on insulin sensitivity, glucose and lipid metabolism and energy expenditure in subjects with type 2 diabetes mellitus.
- Trial name
- NCT00330200
- Testing
- ISIS 113715
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Diabetes
Evaluation of a Nutritional Supplement for People With Type 2 Diabetes.
The objective of this trial is to evaluate a nutritional supplement for people with Diabetes.
- Trial name
- NCT01850134
- Testing
- Experimental Study Product, Control Study Product
- Where
- 2 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Abbott Nutrition
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes
This trial is conducted in Japan. The aim of this trial is to investigate the efficacy and safety of NN5401 (insulin degludec/insulin aspart) with insulin glargine in subjects with type 2 diabetes in Japan.
- Trial name
- BOOST™ (NCT01272193)
- Testing
- insulin degludec/insulin aspart, insulin glargine
- Where
- 50 sites in Japan
- Volunteers
- 296 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
A Study of MK-0893 on Glucagon-Induced Glycemic Excursion in Healthy Male Participants Following Intravenous Administration of Glucagon, Sandostatine® and Insulin (MK-0893-002)
This is a study to assess the pharmacokinetics, safety, and tolerability of sequential single oral doses of MK-8093 10 mg, 40 mg, 200 mg, or placebo to MK-8093 (Part 1) depending on treatment assignment in young healthy male…
- Trial name
- NCT02012166
- Testing
- MK-0893 10 mg, MK-0893 40 mg, MK-0893 200 mg
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
A Phase 1 Study of Ertugliflozin in Healthy Male Participants (MK-8835-020)
This study will evaluate the absolute oral bioavailability (F) and fraction absorbed (Fa) of ertugliflozin following oral administration of unlabeled ertugliflozin (MK-8835) and intravenous (IV) and oral administration of…
- Trial name
- NCT02411929
- Testing
- Unlabeled ertugliflozin for oral use, 14^C-labeled ertugliflozin for IV use, 14^C-labeled ertugliflozin for oral use
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.